326 related articles for article (PubMed ID: 28295450)
1. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies.
Belkoff L; Brock G; Carrara D; Neijber A; Ando M; Mitchel J
Andrologia; 2018 Feb; 50(1):. PubMed ID: 28295450
[TBL] [Abstract][Full Text] [Related]
2. EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
Cunningham G; Belkoff L; Brock G; Efros M; Gittelman M; Carrara D; Neijber A; Ando M; Mitchel J
Endocr Pract; 2017 May; 23(5):557-565. PubMed ID: 28225313
[TBL] [Abstract][Full Text] [Related]
3. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.
Kaminetsky JC; Moclair B; Hemani M; Sand M
J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
5. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies.
Efros M; Carrara D; Neijber A
Andrologia; 2016 Aug; 48(6):637-45. PubMed ID: 26598279
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
7. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
[TBL] [Abstract][Full Text] [Related]
8. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
10. A new testosterone gel (fortesta) for hypogonadism.
Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
Morgentaler A; Benesh JA; Denes BS; Kan-Dobrosky N; Harb D; Miller MG
J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184
[TBL] [Abstract][Full Text] [Related]
12. Review of Testim gel.
McNicholas T; Ong T
Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ
J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
[TBL] [Abstract][Full Text] [Related]
14. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.
Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E
Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839
[TBL] [Abstract][Full Text] [Related]
15. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
[TBL] [Abstract][Full Text] [Related]
16. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
17. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
Rogol AD; Tkachenko N; Bryson N
Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
[TBL] [Abstract][Full Text] [Related]
18. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
Dobs A; Norwood P; Potts S; Gould E; Chitra S
J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
[TBL] [Abstract][Full Text] [Related]
19. Testosterone administration in older men.
Matsumoto AM
Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
